Oncopeptides Future Growth
Future criteria checks 2/6
Oncopeptides is forecast to grow earnings and revenue by 44.1% and 87.4% per annum respectively while EPS is expected to grow by 66.6% per annum.
Key information
44.1%
Earnings growth rate
66.6%
EPS growth rate
| Biotechs earnings growth | 37.0% |
| Revenue growth rate | 87.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 May 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 338 | -43 | -43 | -43 | 1 |
| 12/31/2024 | 177 | -198 | -198 | -198 | 1 |
| 12/31/2023 | 26 | -335 | -362 | -362 | 2 |
| 3/31/2023 | 9 | -310 | -346 | -343 | N/A |
| 12/31/2022 | 8 | -338 | -423 | -421 | N/A |
| 9/30/2022 | -14 | -641 | -790 | -789 | N/A |
| 6/30/2022 | 41 | -1,330 | -1,055 | -1,055 | N/A |
| 3/31/2022 | 99 | -1,294 | -1,296 | -1,296 | N/A |
| 12/31/2021 | 118 | -1,430 | -1,517 | -1,516 | N/A |
| 9/30/2021 | 140 | -1,549 | -1,444 | -1,427 | N/A |
| 6/30/2021 | 86 | -1,155 | -1,449 | -1,431 | N/A |
| 3/31/2021 | 19 | -1,532 | -1,388 | -1,370 | N/A |
| 12/31/2020 | N/A | -1,595 | -1,314 | -1,297 | N/A |
| 9/30/2020 | N/A | -1,327 | -1,159 | -1,156 | N/A |
| 6/30/2020 | N/A | -1,133 | -1,026 | -1,023 | N/A |
| 3/31/2020 | N/A | -904 | -863 | -861 | N/A |
| 12/31/2019 | N/A | -741 | -693 | -691 | N/A |
| 9/30/2019 | N/A | -608 | -583 | -582 | N/A |
| 6/30/2019 | N/A | -512 | -469 | -469 | N/A |
| 3/31/2019 | N/A | -485 | -436 | -436 | N/A |
| 12/31/2018 | N/A | -411 | -334 | -334 | N/A |
| 9/30/2018 | N/A | -368 | -272 | -271 | N/A |
| 6/30/2018 | N/A | -325 | -263 | -262 | N/A |
| 3/31/2018 | N/A | -248 | -246 | -244 | N/A |
| 12/31/2017 | N/A | -250 | -273 | -271 | N/A |
| 9/30/2017 | N/A | -243 | -271 | -270 | N/A |
| 6/30/2017 | N/A | -216 | -214 | -211 | N/A |
| 3/31/2017 | N/A | -172 | -160 | -159 | N/A |
| 12/31/2016 | N/A | -125 | N/A | -104 | N/A |
| 12/31/2015 | N/A | -62 | N/A | -53 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ONCOS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ONCOS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ONCOS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ONCOS's revenue (87.4% per year) is forecast to grow faster than the UK market (4% per year).
High Growth Revenue: ONCOS's revenue (87.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ONCOS's Return on Equity is forecast to be high in 3 years time